← Back to the Areas of Interest
Thermofisher Scientific and Janssen Pharmaceutical – Riding the new waves of success: Latest strategies in the screening and management of NSCLC patients with EGFR exon 20 insertion mutations
Merck Healthcare KGaA – Time to explore treatment options for patients with advanced NSCLC harboring MET alterations
AstraZeneca – Navigating the complexity in NSCLC: Optimising the patient journey
MSD – Shifting paradigms for early-stage NSCLC: Asian oncologists’ perspectives
Roche – The emerging treatment landscape of targeted therapy and personalized healthcare in lung cancer